Login
Register
RSS
News
PubMed
Corporate
Trials
Drugs
Careers
Channels
ReportsBioPortfolio.com - the life science and healthcare portal
BioPortfolio brings our visitors continuously updated biotechnology, pharmaceutical and healthcare news from several hundred selected sources, including syndicated news, blogs and press releases written by our editors and contributors. Our archive contains: over 600,000 news articles; corporate details on 40,000 organizations; 300,000 published medical and life science abstracts; 33,000 profiles on approved drugs; and 65,000 clinical trials.
We offer job seekers the opportunity to search across thousands of biotech, pharma and healthcare jobs; and business development and market researchers access to 20,000 management reports specific to the biotechnology, pharmaceutical and healthcare sectors. Specific Channels provide our users with highly specific web pages that combine related information to provide a quick and authoritative resource on medical conditions, biotechnology and pharmaceutical products and career opportunities. BioPortfolio also provides a life-science event calendar which list forthcoming conferences worldwide.
During 2012 BioPortfolio will be launching a selection of Daily News Digests - subscription is FREE - for example prostate cancer, breast cancer
Latest BioPortfolio blog: Medical shortages in the EU - UK - parallel trade and distortion of the the distribution of prescription drugs
Parallel trade in medicines has been controversial for years, with supporters arguing that it helps to stimulate competition and keep drug prices low across Europe, and critics arguing that it disrupts supplies and prevents patients getting access to dru... — Read more
Latest article: STENTYS Self-Apposing® Stent shows very low mortality at one month in 1,000 high-risk heart attack patients
STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only Self-Apposing® Stent to treat Acute Myocardial Infarction (AMI), announced today the definite results on the 1,000-patient APPOSITION III clinical study at one month after treatment of a severe heart attack. The 30-day rate of MACE (Major Adverse Cardiac Events) and death were compared to a pooled analysis conducted by the ACTION Study Group (Pitié-Salpêtrière Hospital, Prof. G. Montalescot) of all prior recent trials with conventional stents in heart attack patients. APPOSITION III results showed a MACE rate of 3.5% while conventional stents are at an average of 6%; the death rate was 1.2% with STENTYS compared to 3.5% with conventional stents. “When the current guideline on balloon post-dilation was applied, the MACE rate was even lower at 2.5%, which is a drastic improvement f... — Read more
Latest BioPortfolio News
- Discover better powder handling with Freeman Technology at Interphex Japan
- Malvern team presents ‘Nanoparticle characterization by light scattering’ poster at ACS Colloids 2012 symposium
- Thermo Fisher Scientific Introduces Chiral Resolution Screening and Purification Kits
- Lab21 Secures European and USA Patents for HCV Drug Resistance Genotyping.
- New Board Members join PolyTherics - ENHANCED BREADTH OF EXPERIENCE ON POLYTHERICS’ BOARD SUPPORTS NEXT PHASE OF DEVELOPMENT
Latest News From All Sources
- STENTYS Self-Apposing® Stent shows very low mortality at one month in 1,000 high-risk heart attack patients
- BioAmber is Revolutionizing Renewable Chemistry
- Securian Wellness Program Encourages Employees to “Walk This Way”
- More states work to implement health care law
- Dr. Kenneth Blum Joins Malibu Beach Recovery Center as Neuroscience Advisor
Latest Blogs
- Amorfix Announces the Development of Antibodies that Bind to Misfolded Fas Receptor Protein as ...
- Pfizer Provides Topline Results From Phase 3 Study Of Torisel® As Second-Line Treatment In ...
- Inovio Pharmaceuticals' Universal Avian Flu Vaccine Generates Protective Antibody Responses ...
- Elevation Pharmaceuticals Announces Positive Phase 2b Results for EP-101 for the Treatment of ...
- Galectin Therapeutics Announces Initiation of Phase 1/2 Trial of Novel Combination Therapy for ...
Latest Syndicated News
- News and press releases: European Medicines Agency launches new e-learning course for Article 57 (2) requirements on submission of information on medicines
- Human medicines European Public Assessment Report (EPAR): Circadin, melatonin, Revision: 14, Authorised
- [Comment] Pazopanib and the treatment palette for soft-tissue sarcoma
- [Review] Thomas Wakley (1795–1862): a biographical sketch
- [Articles] Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Latest Clinical Trials
- Hypertension Prevention Trial (HPT) Feasibility Study
- Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma
- Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome
- Measuring HIV Quality of Care
- Breast Ultrasound and Mammography in Screening Women at High Risk for Breast Cancer
Latest PubMed Articles
- The changing histological pattern of gastric polyps in an ethnically heterogeneous population.
- Nasalance scores for typical Irish English-speaking adults.
- The burden of inflammatory bowel disease on health care utilization and quality of life.
- Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study.
- The effect of bolus and food calculator Diabetics on glucose variability in children with type 1 diabetes treated with insulin pump: the results of RCT.
Twitter
Linkedin